EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study

Susana Clemente Bautista iD, Óscar Segarra Cantón, Núria Padullés-Zamora, Sonia García García iD, Marina Álvarez Beltrán, María Larrosa García iD, Maria Josep Cabañas Poy, Maria Teresa Sanz-Martínez, Ana Vázquez iD, Maria Queralt Gorgas Torner iD, Marta Miarons iD

Pharmaceutics · 10.12.2024 · 16 (12) · 1577

DOI: 10.3390/pharmaceutics16121577 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 10.12.2024. Verfasst von Susana Clemente Bautista und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sociedad Española de Farmacia Hospitalaria, Hospital Pharmacy of the Fundación Española de Farmacia Hospitalaria (FEFH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study evaluated the long-term effectiveness and safety of a multidisciplinary early proactive therapeutic drug monitoring (TDM) program combined with Bayesian forecasting for infliximab (IFX) dose adjustment in a real-world dataset of paediatric patients with inflammatory bowel disease (IBD).

Methods

A descriptive, ambispective, single-centre study of paediatric patients with IBD who underwent IFX serum concentration measurements between September 2015 and September 2023. The patients received reactive TDM before September 2019 (n = 17) and proactive TDM thereafter (n = 21). We analysed for clinical, biological, and endoscopic remission; treatment failure; hospitalisations; emergency visits; and adverse drug reactions. The IFX doses were adjusted to maintain trough concentrations ≥ 5 µg/mL, with specific targets for proactive TDM.

Results

Of the 38 patients, 21 had Crohn’s disease (CD), 16 ulcerative colitis (UC), and 1 undetermined IBD. The mean (standard deviation) IFX trough concentrations were 6.83 (5.66) µg/mL (reactive) and 12.38 (9.24) µg/mL (proactive) (p = 0.08). No statistically significant differences between groups were found in remission rates or treatment failure. The proactive group had fewer hospitalisations (14.29% vs. 23.53%; p = 0.47) and shorter median hospitalisation days (6 vs. 19; p = 0.50), although the difference was not statistically significant. The number of patients with adverse reactions (infusion related reactions and infections) was higher in the proactive group (38.10% vs. 23.53%; p = 0.34) but the difference was not significantly different.

Conclusions

Proactive TDM showed no significant differences in treatment outcomes compared to reactive TDM. However, the results in both the reactive and proactive TDM groups were not worse than those reported in other studies. Further studies with larger samples are needed to optimize the treatment strategies for pediatric IBD patients.

Schlagwörter

Stichwörter der Autor:innen

childreninflammatory bowel diseasesinfliximabtherapeutic drug monitoring

Autor:innen und Institutionen

  • Pharmacy Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • Paediatric Gastroenterology and Clinical Nutrition Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • Department of Paediatrics, Obstetrics and Gynaecology, Preventive Medicine and Public Health of the Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
  • Pharmacy Department, Hospital Universitari de Bellvitge-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
  • Immunology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • Department of Applied Statistics, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.

ORCID-Profile: Susana Clemente Bautista, Sonia García García, María Larrosa García, Ana Vázquez, Maria Queralt Gorgas Torner, Marta Miarons

Förderung

  • Sociedad Española de Farmacia Hospitalaria
  • Hospital Pharmacy of the Fundación Española de Farmacia Hospitalaria (FEFH)

Zitieren

APA

Clemente Bautista, S., Segarra Cantón, Ó., Padullés-Zamora, N., García García, S., Álvarez Beltrán, M., Larrosa García, M., Cabañas Poy, M. J., Sanz-Martínez, M. T., Vázquez, A., Gorgas Torner, M. Q., & Miarons, M. (2024). Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study. Pharmaceutics, 16(12), 1577. https://doi.org/10.3390/pharmaceutics16121577

Vancouver

Clemente Bautista S, Segarra Cantón Ó, Padullés-Zamora N, García García S, Álvarez Beltrán M, Larrosa García M, et al. Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study. Pharmaceutics. 2024;16(12):1577. doi:10.3390/pharmaceutics16121577

BibTeX
@article{ClementeBautista2024,
  author = {Clemente Bautista, Susana and Segarra Cantón, Óscar and Padullés-Zamora, Núria and García García, Sonia and Álvarez Beltrán, Marina and Larrosa García, María and Cabañas Poy, Maria Josep and Sanz-Martínez, Maria Teresa and Vázquez, Ana and Gorgas Torner, Maria Queralt and Miarons, Marta},
  title = {Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {12},
  pages = {1577},
  doi = {10.3390/pharmaceutics16121577}
}
Kostenlos starten →